MoonLake Immunotherapeutics·4

Jan 9, 4:01 PM ET

Bodenstedt Matthias 4

4 · MoonLake Immunotherapeutics · Filed Jan 9, 2026

Insider Transaction Report

Form 4
Period: 2026-01-07
Bodenstedt Matthias
Chief Financial Officer
Transactions
  • Award

    Class A ordinary shares, par value $0.0001 per share

    2026-01-07+354,2961,276,305 total
Footnotes (1)
  • [F1]Represents shares of restricted stock that vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary